JP6412503B2 - 置換逆ピリミジンＢｍｉ−１阻害剤 - Google Patents

置換逆ピリミジンＢｍｉ−１阻害剤 Download PDF

Info

Publication number
JP6412503B2
JP6412503B2 JP2015544124A JP2015544124A JP6412503B2 JP 6412503 B2 JP6412503 B2 JP 6412503B2 JP 2015544124 A JP2015544124 A JP 2015544124A JP 2015544124 A JP2015544124 A JP 2015544124A JP 6412503 B2 JP6412503 B2 JP 6412503B2
Authority
JP
Japan
Prior art keywords
alkyl
trifluoromethyl
amino
imidazo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504290A (ja
JP2016504290A5 (cg-RX-API-DMAC7.html
Inventor
チャン スン リー
チャン スン リー
ラミル バイアジトフ
ラミル バイアジトフ
リャンシャン カオ
リャンシャン カオ
トマス ダブリュ ディヴィス
トマス ダブリュ ディヴィス
ウー デュ
ウー デュ
ロンガン リウ
ロンガン リウ
ヨン チョン ムーン
ヨン チョン ムーン
スティーヴィン ディー パジェット
スティーヴィン ディー パジェット
ホンギュ レン
ホンギュ レン
ナディヤ シドレンコ
ナディヤ シドレンコ
リチャード ジェラルド ワイルド
リチャード ジェラルド ワイルド
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド, ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2016504290A publication Critical patent/JP2016504290A/ja
Publication of JP2016504290A5 publication Critical patent/JP2016504290A5/ja
Application granted granted Critical
Publication of JP6412503B2 publication Critical patent/JP6412503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
JP2015544124A 2012-11-21 2013-11-21 置換逆ピリミジンＢｍｉ−１阻害剤 Active JP6412503B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018183173A Division JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンＢｍｉ−１阻害剤

Publications (3)

Publication Number Publication Date
JP2016504290A JP2016504290A (ja) 2016-02-12
JP2016504290A5 JP2016504290A5 (cg-RX-API-DMAC7.html) 2017-01-05
JP6412503B2 true JP6412503B2 (ja) 2018-10-24

Family

ID=50776672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015544124A Active JP6412503B2 (ja) 2012-11-21 2013-11-21 置換逆ピリミジンＢｍｉ−１阻害剤
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンＢｍｉ−１阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンＢｍｉ−１阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンＢｍｉ−１阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンＢｍｉ−１阻害剤

Country Status (32)

Country Link
US (3) US10428050B2 (cg-RX-API-DMAC7.html)
EP (1) EP2922828B1 (cg-RX-API-DMAC7.html)
JP (3) JP6412503B2 (cg-RX-API-DMAC7.html)
KR (4) KR102275676B1 (cg-RX-API-DMAC7.html)
CN (2) CN111423417B (cg-RX-API-DMAC7.html)
AR (1) AR093579A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013348009C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015011760B1 (cg-RX-API-DMAC7.html)
CA (1) CA2892045C (cg-RX-API-DMAC7.html)
CL (1) CL2015001377A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150294A (cg-RX-API-DMAC7.html)
CU (1) CU24387B1 (cg-RX-API-DMAC7.html)
DK (1) DK2922828T3 (cg-RX-API-DMAC7.html)
EA (2) EA035349B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15019948A (cg-RX-API-DMAC7.html)
ES (1) ES2821529T3 (cg-RX-API-DMAC7.html)
HK (1) HK1215032A1 (cg-RX-API-DMAC7.html)
IL (2) IL238871B (cg-RX-API-DMAC7.html)
MA (1) MA38208B1 (cg-RX-API-DMAC7.html)
MX (2) MX385385B (cg-RX-API-DMAC7.html)
NI (1) NI201500072A (cg-RX-API-DMAC7.html)
NZ (2) NZ708909A (cg-RX-API-DMAC7.html)
PE (1) PE20151413A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501130B1 (cg-RX-API-DMAC7.html)
PL (1) PL2922828T3 (cg-RX-API-DMAC7.html)
PT (1) PT2922828T (cg-RX-API-DMAC7.html)
SA (1) SA517381847B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201503982XA (cg-RX-API-DMAC7.html)
TW (1) TWI623531B (cg-RX-API-DMAC7.html)
UA (1) UA118094C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014081906A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503642B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503982XA (en) * 2012-11-21 2015-06-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) * 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2018090009A1 (en) 2016-11-14 2018-05-17 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP3911418A1 (en) * 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Method for treating an acute myeloid leukemia
EP3931196A4 (en) * 2019-02-28 2022-12-14 PTC Therapeutics, Inc. Method for treating a multiple myeloma
SG11202109503TA (en) 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof
AU2020248351B2 (en) 2019-03-22 2025-09-25 Cognoa, Inc. Personalized digital therapy methods and devices
WO2020198705A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (cg-RX-API-DMAC7.html) * 1973-09-20 1977-11-30 Delalande Sa
RU2129549C1 (ru) 1994-08-13 1999-04-27 Юхан Корпорейшн Производные пиримидина и способы их получения
IN188411B (cg-RX-API-DMAC7.html) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE60039059D1 (de) 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
JP2004509115A (ja) 2000-09-15 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
IL156784A0 (en) 2001-02-20 2004-02-08 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE60214198T2 (de) 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) * 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
US7259179B2 (en) 2002-05-23 2007-08-21 Cytopia Research Pty Ltd Kinase inhibitors
ATE447560T1 (de) 2002-06-28 2009-11-15 Nippon Shinyaku Co Ltd Amidderivat
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003301302A1 (en) 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
EP1704145B1 (en) 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
PL2332940T3 (pl) * 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
CA2599544A1 (en) 2005-02-28 2006-09-08 Japan Tobacco Inc. Novel aminopyridine compound with syk inhibitory activity
US20110098301A1 (en) 2005-03-10 2011-04-28 Bayer Healthcare Llc Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
ATE549336T1 (de) 2006-10-19 2012-03-15 Signal Pharm Llc Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
EA200900799A1 (ru) 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8680113B2 (en) * 2008-07-01 2014-03-25 Ptc Therapeutics, Inc. BMI-1 protein expression modulators
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2010026087A1 (en) 2008-09-02 2010-03-11 Neurosearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
WO2010092962A1 (ja) 2009-02-12 2010-08-19 アステラス製薬株式会社 へテロ環誘導体
MX2011010105A (es) 2009-03-27 2012-01-12 Pathway Therapeutics Inc Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
EP2435435B1 (en) 2009-05-27 2014-01-29 AbbVie Inc. Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
PL2442809T3 (pl) * 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
EP2454262B1 (en) 2009-07-15 2014-05-14 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
AR079993A1 (es) 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
BR112013003031A2 (pt) * 2010-08-19 2016-06-14 Hoffmann La Roche método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs
MX2013002864A (es) 2010-09-13 2013-08-29 Novartis Ag Triazina-oxadiazoles.
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
MX2013006467A (es) * 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
PL2678331T3 (pl) 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
AU2012280725B2 (en) * 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
SG11201503982XA (en) * 2012-11-21 2015-06-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
KR20220143164A (ko) 2022-10-24
BR112015011760A2 (pt) 2017-07-11
KR102275676B1 (ko) 2021-07-12
CR20150294A (es) 2015-08-20
EA201590992A1 (ru) 2015-11-30
KR20210088740A (ko) 2021-07-14
SG10201600149VA (en) 2016-02-26
JP2016504290A (ja) 2016-02-12
JP6918898B2 (ja) 2021-08-11
US20220064150A1 (en) 2022-03-03
IL238871B (en) 2019-03-31
MX2021009892A (es) 2021-09-14
PE20151413A1 (es) 2015-10-23
ZA201503642B (en) 2020-10-28
IL265253A (en) 2019-05-30
US20150315182A1 (en) 2015-11-05
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
HK1215032A1 (zh) 2016-08-12
KR102356487B1 (ko) 2022-02-08
AR093579A1 (es) 2015-06-10
US20200024260A1 (en) 2020-01-23
KR20150086345A (ko) 2015-07-27
MX2015006469A (es) 2015-10-29
MA38208B1 (fr) 2021-12-31
ECSP15019948A (es) 2016-01-29
JP2020055815A (ja) 2020-04-09
EP2922828B1 (en) 2020-07-08
EA201890142A1 (ru) 2018-06-29
CN111423417A (zh) 2020-07-17
EP2922828A4 (en) 2016-07-27
TWI623531B (zh) 2018-05-11
KR102455889B1 (ko) 2022-10-17
CA2892045A1 (en) 2014-05-30
WO2014081906A3 (en) 2014-07-17
ES2821529T3 (es) 2021-04-26
CN104918919A (zh) 2015-09-16
NZ746607A (en) 2019-11-29
DK2922828T3 (da) 2020-08-31
PL2922828T3 (pl) 2020-12-28
SG11201503982XA (en) 2015-06-29
JP6617186B2 (ja) 2019-12-11
NZ708909A (en) 2019-11-29
IL238871A0 (en) 2015-07-30
PH12015501130B1 (en) 2023-01-27
PT2922828T (pt) 2020-10-12
TW201427972A (zh) 2014-07-16
PH12015501130A1 (en) 2015-08-03
CU20150053A7 (es) 2015-11-27
US11180483B2 (en) 2021-11-23
CU24387B1 (es) 2019-03-04
MX385385B (es) 2025-03-18
JP2019031509A (ja) 2019-02-28
EP2922828A2 (en) 2015-09-30
US10428050B2 (en) 2019-10-01
CL2015001377A1 (es) 2016-02-19
UA118094C2 (uk) 2018-11-26
NI201500072A (es) 2016-01-18
BR112015011760B1 (pt) 2022-12-06
EA035349B1 (ru) 2020-05-29
KR20220016305A (ko) 2022-02-08
AU2013348009C1 (en) 2019-08-08
CN111423417B (zh) 2022-11-15
AU2013348009A1 (en) 2015-06-04
EA031405B1 (ru) 2018-12-28
AU2013348009B2 (en) 2018-05-17
CA2892045C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
JP6617186B2 (ja) 置換逆ピリミジンＢｍｉ−１阻害剤
JP6728321B2 (ja) 置換ピリミジンＢｍｉ−１阻害剤
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
HK40034027B (en) Substituted reverse pyrimidine bmi-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180928

R150 Certificate of patent or registration of utility model

Ref document number: 6412503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350